Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3090106 · 2 trials · 2 indications
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3090106 | EXPERIMENTAL | LY3090106 administered subcutaneously (SC) |
| Placebo | PLACEBO_COMPARATOR | Placebo administered SC |
| Name | Type | Description |
|---|---|---|
| LY3090106 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Overtly healthy Japanese or Caucasian * Body mass index (BMI) 18.0 - 32.0 kilograms per square meter (kg/m²) Exclusion Criteria: * Have participated, within the last 30 days, in a clinical study involving an investigational product (IP). If the previous IP has a long half-li...
LY3090106 is an investigational small molecule being studied for the treatment of Sjögren's syndrome. It has also been evaluated in healthy participants to assess its safety and tolerability. The drug is in Phase 1 clinical development and is not yet approved for any use.
LY3090106 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in Sjögren's syndrome and in healthy volunteers.
LY3090106 is in Phase 1 clinical development. Two Phase 1 trials have been completed: one in participants with Sjögren's syndrome and another in healthy Japanese and Caucasian participants. The drug remains investigational and has not received regulatory approval.
LY3090106 has been studied in two completed Phase 1 trials. NCT02614716 enrolled 32 participants with Sjögren's syndrome in the United States, Bulgaria, Georgia, and Romania. NCT03736772 enrolled 30 healthy Japanese and Caucasian participants in the United States. Both trials were randomized, double-blind, and placebo-controlled.
LY3090106 is the drug name used in clinical trials. No alternative names have been reported for this investigational compound. It is being studied under this identifier by Eli Lilly and Company in its Phase 1 clinical program.